CTL and NK cell product (CytoVac)

N/A

Report date: 2025/02/24 20:01:08

Base Information

Drug NameCTL and NK cell product (CytoVac)

Drug Alias NameALECSATCytotoxic lymphocyte-based cancer vaccine

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy

Mechanisms of ActionNatural killer cells stimulantsCytotoxic T lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsPancreatic NeoplasmsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenDenmark

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCytovac A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCytovac A/S

Active IndicationsN/A

Inactive IndicationsHormone-Resistant Prostate NeoplasmsPancreatic NeoplasmsGlioblastoma

Other Information

ATC CodeN/A